IrelandIreland

Label change for Elan's MS-drug permits safer use

24.01.2012

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the JC-virus marks a higher risk of developing progressive multifocal leukoencephalopathy (PML). A new label identifies anti-JCV antibody status as a third risk factor for developing PML. Tysabri (natalizumab) increases the risk of PML, an opportunistic viral infection of the brain which in most cases leads to death or severe disability. With the label update, which the companies say was inspired by their own research, physicians now have others factor at hand when weighing the risks and benefits of applying Tysabri. “We welcome the inclusion of PML risk stratification in the U.S. label as it significantly supports our aim to provide the information patients and physicians need to make a more informed treatment decision,” said Kelly Martin, CEO of Elan. Tysabri is approved in about 65 countries and results in a 68% relative reduction in the annualised relapse rate when compared with placebo, according to studies conducted by Elan.

IrelandIreland

20.03.2012

While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided...

IrelandIreland

16.03.2012

Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved....

IrelandIreland

07.03.2012

Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and...

IrelandIreland

13.12.2011

Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research...

IrelandIreland

07.12.2011

Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of...

IrelandIreland

05.12.2011

Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex...

IrelandIreland

01.10.2011

Athlone – Biopharma group Alkermes has established its new Irish corporate base following its merger with Elan Drug Tech­nologies. The a712m (US$960m) deal agreed back in May – which saw Alkermes acquire Elan’s Athlone-based drug...

IrelandIreland

21.09.2011

Palo Alto/Dublin - Jazz Pharmaceuticals Inc. has bought Azur Pharma Limited in an all-stock deal that will create a specialty pharmaceutical company incorporated in Ireland. Shareholders of Jazz will own nearly 80 percent of the...

Displaying results 1 to 10 out of 49

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-ireland/article/label-change-for-elans-ms-drug-permits-safer-use.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.2%
  • VITA 344.32 EUR8.0%
  • BB BIOTECH157.70 EUR7.3%

FLOP

  • PAION2.24 EUR-30.0%
  • CYTOS0.16 CHF-27.3%
  • MAGFORCE5.90 EUR-17.5%

TOP

  • SANTHERA85.50 CHF2335.9%
  • CO.DON2.75 EUR192.6%
  • PAION2.24 EUR163.5%

FLOP

  • CYTOS0.16 CHF-95.8%
  • THERAMETRICS0.08 CHF-42.9%
  • 4SC0.97 EUR-42.6%

No liability assumed, Date: 23.10.2014


Current issue

All issues

Product of the week

Products